Incyte Corporation (INCY)

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor R...

Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

Incyte Corporation  INCY reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.

Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.